Americas · Regional markets · Financial Post

Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer

Published by Financial Post · Canada 2 h ago

Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of…

Read the full article on Financial Post Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (financialpost.com)

Also worth reading

BNN Bloomberg

CTV News Exclusive: Indian High Commissioner ‘confident’ trade deal will be reached by November

La República

La aerolínea Air Canada vuelve a Perú y apunta a ocupaciones superiores a 90%

Ámbito

Quién será más rico dentro de diez años, Salinas Pliego o Carlos Slim: esto dice la Inteligencia Artificial

Gestión

Qué pasó al final de “Lupin” - Temporada 4: el misterio del impostor y el disparo que cambia el futuro de Assane Diop

El Cronista

Avanzan las negociaciones para aumentar el salario mínimo a partir del 1 de enero: las declaraciones de Claudia Sheinbaum

Diario Financiero